Prostate Cancer
Conditions
Keywords
Prostate cancer, PET / CT, Ga-PSMA
Brief summary
This is a phase II clinical trial study to show how well the 68Ga-PSMA-11 (ProstaMedix™) PET-CT scan works in detecting tumor location and size in patients with suspected or confirmed prostate cancer, as well as prostate cancer that may have come back in patients with elevated PSA ( a prostate-specific antigen tumor marker) after initial treatment.
Detailed description
68Ga-PSMA-11 is a radioactive imaging contrast agent for use in PET CT scan that seeks to identify prostate cancer cells that have a specific protein target called prostate-specific membrane antigen (PSMA) on their surface. PET and CT make computerizing pictures of areas inside the body where the radioactive substance is lighting up. 68Ga-PSMA-11 PET / CT may be able to see smaller tumors than standard imaging and may help determine whether prostate cancer has come back and where it is in the body. A 68Ga-PSMA-11 PET / CT scan may help doctors to better detect the location, extent, and characteristics of the tumor, allowing improved planning of subsequent therapy
Interventions
DRUG68Ga-PSMA
Patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging (MRI). Suspected prostate recurrence is based upon elevated blood prostate specific antigen (PSA) levels following initial therapy.
Sponsors
Radiomedix, Inc.
Excel Diagnostics and Nuclear Oncology Center
Ebrahim Delpassand
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
General requirements: 1. Karnofsky performance status of ≥50 (or ECOG/WHO equivalent). 2. Age \> 18 years . 3. Ability to understand a written informed consent document, and the willingness to sign it. 4. i. inclusion criteria specific for the pre-prostatectomy group: * Biopsy proven prostate adenocarcinoma. * Planned prostatectomy with lymph node dissection. * Intermediate to high-risk disease (as determined by elevated PSA \[PSA\>10\], T-stage \[T2b or greater\], Gleason score \[Gleason score \> 6\] or other risk factors). 4\. ii. inclusion criteria specific for biochemical recurrence group: * Histopathological proven prostate adenocarcinoma. * Rising PSA after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy). 1. Post radical prostatectomy (RP) - AUA recommendation, PSA greater than or equal to 0.2 ng/mL measured more than 6 weeks after RP. 2. Post-radiation therapy -ASTRO-Phoenix consensus definition, Nadir + greater than or equal to 2 ng/mL rise in PSA 5. Diagnostic CT or MRI as part of the PET study or performed within one month of PSMA PET
Exclusion criteria
General requirements: 1. Patients not capable of getting PET study due to weight, claustrophobia, or inability to lay still for the duration of the exam. 2. Contraindication to furosemide administration including prior allergy or adverse reaction to furosemide or sulfa drugs. (Note: This exclusion criterion can be removed if Furosemide is omitted as part of the PET imaging protocol if a second-generation scatter correction is available for the used PET device). 3. i.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The sensitivity of 68Ga-PSMA-11 PET for detection of tumor location. | 12 months | The sensitivity of 68Ga-PSMA-11 PET to detect tumor location and metastases in patients with biopsy confirmed diagnosis.tumor location confirmed by histopathology/biopsy and conventional imaging follow-up. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Detection rates of 68Ga-PSMA-11 PET in patients with different PSA value | 12 months | Detection rates of 68Ga-PSMA-11 PET in patients with different PSA value (0.2 - \<0.5, 0.5 - \<1.0, 1.0 - \<2.0, 2.0 - \<5.0, 5.0). |
Countries
United States
Contacts
Primary ContactSusan Cork
Backup ContactRodolfo Nunez, MD
Outcome results
None listed